TG Therapeutics, Inc.
Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor

Abstract:

Highly effective combinations of a compound of formula A (a PI3K.delta. selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K.delta. and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provides for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma. The invention also provides for a combination of a compound of formula A, or stereoisomers thereof, and anti-CD20 antibodies, including ublituximab for the treatment and/or amelioration of multiple scelrosis.